Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Belzutifan

FDA-approved product (tablet, oral), marketed as Welireg.

Registered studies
45
Lab records
0
Pathogens at ≥40%
2 of 4

Chemical structure

Chemical structure of Belzutifan
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Clear cell renal carcinoma
  • Hemangioblastoma
  • Neoplasm
  • Pancreatic neuroendocrine tumor
  • Renal cell adenocarcinoma
  • Renal cell carcinoma
  • Von Hippel-Lindau disease

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Other antineoplastic agents
FDA pharmacologic class
Hypoxia-inducible Factor Inhibitor FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis and MRSA. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA40.5% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli35.8% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae30.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis62.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

45registered studies name this medicine, for any condition. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Belzutifan in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-8.0 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-7.6 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-8.5 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-8.5 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Belzutifan with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Belzutifan in Recurrent Clear Cell Carcinoma of Gynecologic Origin

    NCT06677190 · start 2024-12-20

    Registered record
    Registry ID
    NCT06677190
    Conditions
    Ovarian Cancer; Ovarian Carcinoma; Endometrial Cancer; Uterine Cancer; Cervical Cancer; Vulvar Cancer; Gynecologic Cancer; Vaginal Cancer
    Interventions
    Belzutifan
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2024-12-20
    Completion
    2029-06-30
    Enrolment
    32

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOvarian Cancer; Ovarian Carcinoma; Endometrial Cancer; Uterine Cancer +4 more
    InterventionBelzutifan
    PhasePhase 2
    Registry statusRecruiting

  • Drug Screening Using Novel IMD in Renal Cell Carcinoma

    NCT05700461 · start 2024-12-01

    Registered record
    Registry ID
    NCT05700461
    Conditions
    Renal Cell Carcinoma; Metastatic Renal Cell Carcinoma; Kidney Cancer
    Interventions
    Implantable Microdevice (IMD)
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Recruiting
    Start
    2024-12-01
    Completion
    2029-08-31
    Enrolment
    20

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRenal Cell Carcinoma; Metastatic Renal Cell Carcinoma; Kidney Cancer
    InterventionImplantable Microdevice (IMD)
    PhasePhase 1
    Registry statusRecruiting

  • Study of Belzutifan (MK-6482) Plus Fulvestrant for ER+/HER2- Metastatic Breast Cancer (MK-6482-029/LITESPARK-029)

    NCT06428396 · start 2024-11-27

    Registered record
    Registry ID
    NCT06428396
    Conditions
    Metastatic Breast Cancer
    Interventions
    Belzutifan; Fulvestrant; Everolimus; Exemestane
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Active not recruiting
    Start
    2024-11-27
    Completion
    2028-12-25
    Enrolment
    120

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMetastatic Breast Cancer
    InterventionBelzutifan; Fulvestrant; Everolimus; Exemestane
    PhasePhase 2
    Registry statusActive not recruiting

  • MSD Belzutifan PAS

    NCT06554730 · start 2024-06-30

    Registered record
    Registry ID
    NCT06554730
    Conditions
    Von Hippel Lindau Disease
    Interventions
    Belzutifan
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Withdrawn
    Start
    2024-06-30
    Completion
    2030-12-31
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionVon Hippel Lindau Disease
    InterventionBelzutifan
    PhaseNot recorded
    Registry statusWithdrawn

  • A Study of HC-7366 in Combination With Belzutifan (WELIREG™) in Patients With Renal Cell Carcinoma

    NCT06234605 · start 2024-04-29

    Registered record
    Registry ID
    NCT06234605
    Conditions
    Renal Cell Carcinoma
    Interventions
    HC-7366; Belzutifan
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Recruiting
    Start
    2024-04-29
    Completion
    2027-11
    Enrolment
    80

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRenal Cell Carcinoma
    InterventionHC-7366; Belzutifan
    PhasePhase 1
    Registry statusRecruiting

  • A Neoadjuvant Study of Abiraterone Acetate, Leuprolide Acetate, and Belzutifan in Men With Regional Prostate Cancer

    NCT05574712 · start 2024-01-01

    Registered record
    Registry ID
    NCT05574712
    Conditions
    Prostate Cancer
    Interventions
    Neoadjuvant treatment
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Withdrawn
    Start
    2024-01-01
    Completion
    2026-07
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstate Cancer
    InterventionNeoadjuvant treatment
    PhasePhase 2
    Registry statusWithdrawn

  • Real-World Effectiveness and Pharmacogenetics of Belzutifan in VHL Syndrome: The BELIEVE-VHL Trial

    NCT07167329 · start 2024-01-01

    Registered record
    Registry ID
    NCT07167329
    Conditions
    Von Hippel Lindau; Von Hippel Lindau Disease; Von Hippel Lindau-Deficient Clear Cell Renal Cell Carcinoma; Hemangioblastoma (HB) of the Central Nervous System (CNS); PNET; Retinal Angiomatous Proliferation; Pheochromocytoma/Paraganglioma; Endolymphatic Sac Tumor
    Interventions
    Belzutifan
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2024-01-01
    Completion
    2030-01-01
    Enrolment
    100

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionVon Hippel Lindau; Von Hippel Lindau Disease; Von Hippel Lindau-Deficient Clear Cell Renal Cell Carcinoma; Hemangioblastoma (HB) of the Central Nervous System (CNS) +4 more
    InterventionBelzutifan
    PhasePhase 2
    Registry statusRecruiting

  • A Study of Belzutifan (MK-6482) in Combination With Palbociclib Versus Belzutifan Monotherapy in Participants With Advanced Renal Cell Carcinoma (MK-6482-024/LITESPARK-024)

    NCT05468697 · start 2022-08-10

    Registered record
    Registry ID
    NCT05468697
    Conditions
    Renal Cell Carcinoma
    Interventions
    Belzutifan; Palbociclib
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Active not recruiting
    Start
    2022-08-10
    Completion
    2026-10-22
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRenal Cell Carcinoma
    InterventionBelzutifan; Palbociclib
    PhasePhase 1 / Phase 2
    Registry statusActive not recruiting

  • A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, vs Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)-China Extension Study

    NCT05899049 · start 2022-07-27

    Registered record
    Registry ID
    NCT05899049
    Conditions
    Carcinoma, Renal Cell
    Interventions
    Pembrolizumab; Belzutifan; Pembrolizumab/Quavonlimab; Lenvatinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Active not recruiting
    Start
    2022-07-27
    Completion
    2027-04-22
    Enrolment
    251

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCarcinoma, Renal Cell
    InterventionPembrolizumab; Belzutifan; Pembrolizumab/Quavonlimab; Lenvatinib
    PhasePhase 3
    Registry statusActive not recruiting

  • A Study of Belzutifan (MK-6482) in Participants With Renal Impairment (MK-6482-021)

    NCT04994522 · start 2022-07-12

    Registered record
    Registry ID
    NCT04994522
    Conditions
    End Stage Renal Disease; Renal Impairment
    Interventions
    Belzutifan
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2022-07-12
    Completion
    2024-04-11
    Enrolment
    14

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionEnd Stage Renal Disease; Renal Impairment
    InterventionBelzutifan
    PhasePhase 1
    Registry statusCompleted

  • A Study of Belzutifan (MK-6482) in Participants With Hepatic Impairment (MK-6482-020)

    NCT04995484 · start 2022-06-24

    Registered record
    Registry ID
    NCT04995484
    Conditions
    Moderate Hepatic Impairment
    Interventions
    Belzutifan
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2022-06-24
    Completion
    2024-01-03
    Enrolment
    17

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionModerate Hepatic Impairment
    InterventionBelzutifan
    PhasePhase 1
    Registry statusCompleted

  • A Study of Belzutifan (MK-6482) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Clear Cell Renal Cell Carcinoma Post Nephrectomy (MK-6482-022)

    NCT05239728 · start 2022-03-15

    Registered record
    Registry ID
    NCT05239728
    Conditions
    Carcinoma, Renal Cell
    Interventions
    Belzutifan; Pembrolizumab; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Active not recruiting
    Start
    2022-03-15
    Completion
    2029-09-28
    Enrolment
    1,800

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCarcinoma, Renal Cell
    InterventionBelzutifan; Pembrolizumab; Placebo
    PhasePhase 3
    Registry statusActive not recruiting

  • A Study of Belzutifan (MK-6482) as Monotherapy and in Combination With Lenvatinib (E7080/MK-7902) With or Without Pembrolizumab (MK-3475) in China Participants With Advanced Renal Cell Carcinoma (MK-6482-010)

    NCT05030506 · start 2021-10-13

    Registered record
    Registry ID
    NCT05030506
    Conditions
    Renal Cell Carcinoma
    Interventions
    Belzutifan; Pembrolizumab; Lenvatinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Active not recruiting
    Start
    2021-10-13
    Completion
    2027-06-30
    Enrolment
    45

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRenal Cell Carcinoma
    InterventionBelzutifan; Pembrolizumab; Lenvatinib
    PhasePhase 1
    Registry statusActive not recruiting

  • Pembrolizumab Plus Lenvatinib in Combination With Belzutifan in Solid Tumors (MK-6482-016)

    NCT04976634 · start 2021-08-18

    Registered record
    Registry ID
    NCT04976634
    Conditions
    Neoplasm Malignant
    Interventions
    Pembrolizumab; Belzutifan; Lenvatinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Active not recruiting
    Start
    2021-08-18
    Completion
    2027-03-22
    Enrolment
    730

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNeoplasm Malignant
    InterventionPembrolizumab; Belzutifan; Lenvatinib
    PhasePhase 2
    Registry statusActive not recruiting

  • [18F]PT2385 PET/CT in Patients With Renal Cell Carcinoma

    NCT04989959 · start 2021-08-18

    Registered record
    Registry ID
    NCT04989959
    Conditions
    Renal Cell Carcinoma; Clear Cell Renal Cell Carcinoma
    Interventions
    [18F]PT2385; Positron Emission Tomography/Computed Tomography; Biopsy
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Recruiting
    Start
    2021-08-18
    Completion
    2027-08-18
    Enrolment
    35

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRenal Cell Carcinoma; Clear Cell Renal Cell Carcinoma
    Intervention[18F]PT2385; Positron Emission Tomography/Computed Tomography; Biopsy
    PhasePhase 1
    Registry statusRecruiting